Vnitr Lek 2019, 65(2):136-142 | DOI: 10.36290/vnl.2019.027

Current trends in immunosuppressive treatment

Marta Sobotková*, Jiřina Bartůňková
Ústav imunologie 2. LF UK a FN Motol, Praha

Immunosuppressive agents represent a class of drugs that inhibits activity of the immune system. They are mostly used in autoimmune diseases and other inflammatory conditions treatment and in prevention of recipient's immune response to donors antigens in transplantations. There is a broad spectrum of different immunosuppressive drugs with various mechanisms of action. This article provides an overview of drugs currently registered as immunosuppressive agents in the Czech Republic and provides some insights what we might expect regarding this group of drugs in the future.

Keywords: biologic treatment; fusion proteins; immunosuppression; kinase inhibitors; monoclonal antibodies; tolerance

Received: June 26, 2018; Accepted: November 26, 2018; Published: February 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sobotková M, Bartůňková J. Current trends in immunosuppressive treatment. Vnitr Lek. 2019;65(2):136-142. doi: 10.36290/vnl.2019.027.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hynie S. Speciální farmakologie. Díl VII/A. Protinádorová chemoterapeutika a imunomodulační látky. 2 vyd. Karolinum: Praha 2003: 104-130. ISBN 80-246-0656-9.
    2. Bartůňková J, Šedivá A, Janda A. Imunodeficience. 2. vyd. Grada: Praha 2007: 192-197.ISBN 978-80-247-1980-1.
    3. Pavelka K, Arenberger P, Lukáš M et al. Biologická léčba zánětlivých autoimunitních onemocnění v revmatologii, gastroenterologii a dermatologii. Grada: Praha 2014: 3-7. ISBN 978-80-247-5048-4.
    4. Databáze léků. Státní ústav pro kontrolu léčiv. Dostupné z WWW: <www.sukl.cz>
    5. Lloyd M. Philip Showalter Hench, 1896-1965. Rheumatology (Oxford) 2002; 41(5): 582-584. Go to original source... Go to PubMed...
    6. Pavelka K, Rovenský J. Klinická revmatologie. Galén: Praha 2003: 773-828. ISBN 80-7262-174-2.
    7. Pavelka K. Nová doporučení pro léčbu revmatoidní artritidy. Postgraduální medicína 2017; 19(1): 6-12.
    8. Murray JE. Nobel Prize Lecture: The first succesful transplant in man. Dostupné z WWW: <https://web.stanford.edu/dept/HPS/transplant/html/murray.html>. [cit. 14. 6. 2018]
    9. Pellegrino B. Immunosuppression. Dostupné z WWW: <https://emedicine.medscape.com/article/432316-overviewServer>.
    10. Matl I. Léčba lupusové nefritidy. Interní Med Praxi 2012; 14(5): 206-208.
    11. Thon V. Teriflunomid v léčbě relabující-remitující formy roztroušené sklerózy - imunomodulační mechanismy. Neurol praxi 2016; 17(1): 52-54. Go to original source...
    12. Thiyagarajan UM, Ponnuswamy A, Bagul A. Thymoglobulin and its use in renal transplantation: a review. Am J Nephrol 2013; 37(6): 586-601. Dostupné z DOI: <http://dx.doi.org/10.1159/000351643>. Go to original source... Go to PubMed...
    13. Sobotková M, Bartůňková J. Antibiotická imunosupresiva. Remedia 2008; 18(3): 233-241.
    14. Perenyei M, Jayne DR, Floßmann O. Gusperimus: immunological mechanism and clinical applications. Rheumatology (Oxford) 2014; 53(10): 1732-1741. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/ket451>. Go to original source... Go to PubMed...
    15. Imbach P. Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. A historical review. Swiss Med Wkly 2012; 142:w13593. Dostupné z DOI: <http://dx.doi.org/10.4414/smw.2012.13593>. Go to original source... Go to PubMed...
    16. Sobotková M, Bartůňková J. Monoklonální protilátky a další biologická léčiva užívaná v imunosupresivní léčbě. Remedia 2008; 18(5): 356-364.
    17. Smith SL. Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord 1996; 6(3): 109-119. Go to original source... Go to PubMed...
    18. Czajkowsky DM, Hu J, Shao Z et al. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 2012; 4(10): 1015-1028. Dostupné z DOI: <http://dx.doi.org/10.1002/emmm.201201379>. Go to original source... Go to PubMed...
    19. Havrdová E. Fingolimod. Remedia 2011; 21(4): 297-303. Go to original source...
    20. Vašáková M. Pirfenidon v léčbě idiopatické plicní fibrózy. Remedia 2015; 25(1): 61-66.
    21. Šterclová M, Vašáková M. Nintedanib. Remedia 2016; 26(1): 39-42.
    22. Hardinger KL, Brennan DC. Novel immunosuppressive agents in kidney transplantation. World J Transplant 2013; 3(4): 68-77. Dostupné z DOI: <http://dx.doi.org/10.5500/wjt.v3.i4.68>. Go to original source... Go to PubMed...
    23. White JR, Phillips F, Monaghan T et al. Review article: novel oral-targeted therapies in inflammatory bowel disease. Aliment Pharmacol Ther 2018; 47(12): 1610-1622. Dostupné z DOI: <http://dx.doi.org/10.1111/apt.14669>. Go to original source... Go to PubMed...
    24. Faissner S, Gold R. Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010. CNS Drugs 2018; 32(3): 269-287. Dostupné z DOI: <http://dx.doi.org/10.1007/s40263-018-0488-6>. Go to original source... Go to PubMed...
    25. Paul F, Murphy O, Pardo S et al. Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin Investig Drugs 2018; 27(3): 265-271. Dostupné z DOI: <http://dx.doi.org/10.1080/13543784.2018.1443077>. Go to original source... Go to PubMed...
    26. Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol 2007; 7(9): 665-677. Dostupné z DOI: <http://dx.doi.org/10.1038/nri2153>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.